A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer
Phase 1
- Conditions
- MedDRA version: 22.1Level: PTClassification code: 10082915Term: Neuroendocrine carcinoma of prostate Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]Adult subjects with de novo or treatment-emergent neuroendocrine prostate cancer
- Registration Number
- CTIS2024-513316-10-00
- Lead Sponsor
- Amgen Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Male
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method